Phase 4
Completed N=6
A Study Evaluating the Efficacy and Tolerability of Enstilar Foam in Patients With Nail Psoriasis
Nail Psoriasis
Source: ClinicalTrials.gov NCT04227288 ↗
Enrolled (actual)
6
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Clinical Improvement in Nail Thickness of Target Nail at Week 24 Compared to Baseline. — 2 Participants who experienced improvement
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
The aim of the study is to evaluate the efficacy and safety of Enstilar Foam (calcipotriene and betamethasone dipropionate) for the treatment of nail psoriasis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Clinical Improvement in Nail Thickness of Target Nail at Week 24 Compared to Baseline. |
2 | — |
| SECONDARY Modified mNAPSI (Modified Nail Area Psoriasis Severity Index) Score of Fingernails at Week 24 Compared to Baseline |
18 | — |
Eligibility Criteria
Inclusion Criteria
- Must have a diagnosis of nail psoriasis in fingernail or toenails
- History of plaque psoriasis or psoriatic arthritis
- Target nail will be KOH negative for dermatophyte fungus
- Must give written informed consent prior to study procedures being conducted, also give consent to the release and use of protected health information (PHI)
- Between the ages of 18 and 85 years old
- Candidate for topical therapy in the opinion of the investigator
Exclusion Criteria
- Males and Females unable to practice effective contraception throughout the study
- Unable to comply with the protocol
- Nursing mothers, pregnant women, and women planning to become pregnant while in this study
- Patients with erythrodermic or pustular psoriasis
- Sustained treatment to target fingernail within 6 months prior to screening
- History of trauma or surgery to target fingernail
- History of disease known to affect nails such as lichen planus, onychomycosis
- History of systemic psoriasis therapy for less than 6 months
Data sourced from ClinicalTrials.gov (NCT04227288). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.